2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Vaccines, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Biological Processes, Apoptosis, Metabolism, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Study Population, Human, Adult, Elderly
PAPER

5149 Outcomes of patients with relapsed/refractory acute myeloid leukemia treated on Phase I clinical trials: A large single-center experience

Alex Bataller, MD, PhD, Manuel M. Maroun, MD2, Omer Karrar, MD3, Abhishek Maiti, MBBS4, Ghayas C. Issa, MD5, Ian Bouligny, M.D.6, Wei Ying Jen, BM BCh, FRCPath7, Guillermo Montalban-Bravo, MD8, Kelly Sharon Chien, MD9, Hannah Goulart, MD10, Hussein Ali Abbas, MD, PhD11, Tapan Kadia I, MD12, Farhad Ravandi, MD13, Naval Daver, MD14, Courtney DiNardo, MD, MSCE15, Guillermo Garcia-Manero, MD16, Gautam Borthakur, MD17, Nicholas Short, MD18
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Introduction: For many pts with relapsed/refractory (R/R) acute myeloid leukemia (AML) who have exhausted standard of care, phase I trials are the only remaining option, offering access to novel therapies with hope of remission while advancing AML drug development. Although outcomes are expected to be poor, response rates and survival after enrollment have not been systematically evaluated. This information could aid shared decision-making between physician and patient when weighing further therapy versus supportive/palliative care. Herein, we report outcomes of pts with R/R AML enrolled in phase I trials at our center.

Methods: We retrospectively analyzed pts with R/R AML enrolled into phase I clinical trials between January 2015 and December 2024. We limited the analysis to pts treated on phase I trials evaluating investigational drugs (i.e. not approved for any indication) administered as monotherapy. Combination studies were excluded, as most of these included second agents with known clinical activity in AML. For pts enrolled into multiple consecutive phase I studies, baseline characteristics and survival analyses were assessed at the time of their earliest phase I trial entry; for response assessment, individual treatment entries were used. Overall response rate (ORR) was defined as complete remission (CR) + CR with incomplete count recovery (CRi) + morphologic leukemia-free state (MLFS).

Results: A total of 446 pts with R/R AML were included, accounting for 537 total instances of phase I trial enrollment across 87 studies. The median age was 67 years (range, 18-86). Pts had received 1 prior line (16%), 2 prior lines (26%), or ≥3 prior lines (58%) of AML therapy. Diploid cytogenetics were present in 17% of pts, and adverse-risk cytogenetics in 55% (including 8% with KMT2A rearrangement and 11% with MECOM rearrangement). The most frequent mutation was TP53, detected in 31%. 85 pts (21%) had a potentially targetable mutation, including IDH1 (4%), IDH2 (8%), FLT3-ITD (2%), FLT3-TKD (4%), and NPM1 (6%). Therapy instances were categorized by mechanism of action: immunotherapy (n= 203, 38%), molecularly targeted inhibitors (n= 121, 23%), or other agents (n= 213, 40%). Among immunotherapies, bispecific antibodies accounted for 15%, antibody-drug conjugates (ADCs) for 11%, unconjugated antibodies for 8%, and cellular therapy for 4%.

Among the 446 pts, 373 (84%) were treated on 1 phase I clinical trial, 59 (13%) on 2 phase I trials, 10 (2%) on 3 phase I trials, and 4 (1%) on 4 phase I trials. Across all treatment entries (n=537), the ORR was 8%, and the CR/CRi rate was 5% (CR 2%; CRi 3%; MLFS 3%). When stratified by TP53 mutation status, the ORR was 4% for TP53-mutated pts versus 9% for TP53 wild-type pts (P=0.05). ORR for immunotherapy, molecular targeted inhibitors, and other agents were 10%, 12% and 3%, respectively (P=0.002), and the CR/CRi rates were 7%, 7% and 2%, respectively (P=0.02). Among immunotherapies, the ORR was 18% for cellular therapy, 9% for bispecific antibodies, 13% for ADCs, and 5% for unconjugated antibodies. Among pts treated with targeted therapy, the ORR was significantly higher in pts harboring the genetic abnormality targeted by the experimental drug versus those without the abnormality (21% vs 5% (P=0.006).

With a median follow-up of 76.8 months, the median overall survival (OS) of the entire cohort was 3.3 months, with a 1-year OS rate of 10%. The 30-day and 60-day mortality rates were 13% and 31%, respectively. Median OS and 1-year OS were 3.7 months and 8%, respectively, for pts receiving immunotherapy; 3.4 months and 16% for pts receiving molecularly targeted inhibitors; and 2.8 months and 9% for pts receiving other therapies (P=0.22). The median relapse-free survival (RFS) was 2.1 months, with a 1-year RFS of 20%. Five pts (1% overall, 12% of responders) proceeded to allogeneic hematopoietic stem cell transplantation after achieving response.

Conclusions: Over this 10-year period, ORR for pts with R/R AML in phase I trials was 8%, with median OS of 3 months and 1-year OS of 10%. Mutation-specific targeted therapies showed the highest ORR (21% in pts harboring the genetic target), consistent with recent approvals of several targeted therapies for R/R AML. These data provide a baseline for counseling pts on realistic expectations for response and prognosis. Despite low response rates, early-phase trials remain essential for advancing AML outcomes.

Alex Bataller, MD, PhD: No relevant conflicts of interest to declare.